Luc Tanguay - Theratechnologies President, Chief Executive Officer, Director

TH Stock  CAD 1.80  0.05  2.70%   

CEO

Mr. Luc Tanguay is President, Chief Executive Officer, Director of Theratechnologies, Inc. Mr. Tanguay was active in the biotechnology industry for over 20 years. As a member of our senior management since 1996, he has contributed to our growth by facilitating access to public and private capital funding. A member of the board of directors since 1993, he has held various management positions since joining the Company. Prior to joining us, Mr. Tanguay had a career in investment banking at National Bank Financial Inc. Mr. Tanguay obtained his M. Sc. Finance from the University of Sherbrooke. since 2014.
Age 57
Tenure 10 years
Address 2015 Peel Street, Montreal, QC, Canada, H3A 1T8
Phone514 336 7800
Webhttps://www.theratech.com

Theratechnologies Management Efficiency

The company has return on total asset (ROA) of (0.0455) % which means that it has lost $0.0455 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (11.1686) %, meaning that it generated substantial loss on money invested by shareholders. Theratechnologies' management efficiency ratios could be used to measure how well Theratechnologies manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of April 2024, Return On Equity is likely to grow to 1.39, while Return On Tangible Assets are likely to drop (0.44). At this time, Theratechnologies' Non Current Assets Total are very stable compared to the past year. As of the 26th of April 2024, Other Current Assets is likely to grow to about 10 M, while Total Assets are likely to drop about 65.2 M.
The company has accumulated 7.29 M in total debt with debt to equity ratio (D/E) of 6.46, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Theratechnologies has a current ratio of 1.86, which is within standard range for the sector. Debt can assist Theratechnologies until it has trouble settling it off, either with new capital or with free cash flow. So, Theratechnologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Theratechnologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Theratechnologies to invest in growth at high rates of return. When we think about Theratechnologies' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 4 records

CEO Age

Michael SiftonData Communications Management
56
Marcel HilmerForsys Metals Corp
N/A
Michael EnglandArbor Metals Corp
52
Richard KellamData Communications Management
58
Theratechnologies Inc., a biopharmaceutical company, markets prescription products in the United States, Europe, and Canada. The company was founded in 1993 and is headquartered in Montreal, Canada. THERATECHNOLOGIES operates under Drug ManufacturersSpecialty Generic classification in Canada and is traded on Toronto Stock Exchange. It employs 42 people. Theratechnologies (TH) is traded on Toronto Exchange in Canada and employs 103 people. Theratechnologies is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Theratechnologies Leadership Team

Elected by the shareholders, the Theratechnologies' board of directors comprises two types of representatives: Theratechnologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Theratechnologies. The board's role is to monitor Theratechnologies' management team and ensure that shareholders' interests are well served. Theratechnologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Theratechnologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
MarieNoel Colussi, Vice President - Finance
Luc Tanguay, President, Chief Executive Officer, Director
Jovan Antunovic, Senior Vice President and Chief Commercial Office
Conor Walshe, General Manager - Theratechnologies Europe Limited
Sheila Frame, Independent Director
Paul Lvesque, CEO President
Philippe Dubuc, Chief Financial Officer, Senior Vice President
Paul Levesque, President, Chief Executive Officer, Director
Andrew Molson, Independent Director
Gerald Lacoste, Independent Director
LLB LLM, General Secretary
Dawn Svoronos, Independent Chairman of the Board
Pierre Perazzelli, Vice President - Pharmaceutical Development
LLB BA, VP Affairs
Denis Boucher, Vice President - Communications and Corporate Affairs
H MSc, Vice Resources
Chantal Placais, Executive Assistant
Lyne Fortin, Senior Vice President Chief Commercial Officer
Christian Marsolais, Senior Vice President - Scientific Affairs and Alliances
John Leasure, Global Officer
Paul Pommier, Independent Director
Gilles Cloutier, Independent Director
Gary Littlejohn, Independent Director
JeanDenis Talon, Independent Director
Elif McDonald, Director Relations
Jocelyn Lafond, Vice President - Legal Affairs, Corporate Secretary
Alain Trudeau, Independent Director
MBA MBA, Senior CFO
Dale Weil, Independent Director

Theratechnologies Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Theratechnologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether Theratechnologies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Theratechnologies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Theratechnologies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Theratechnologies Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theratechnologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
To learn how to invest in Theratechnologies Stock, please use our How to Invest in Theratechnologies guide.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Theratechnologies Stock analysis

When running Theratechnologies' price analysis, check to measure Theratechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theratechnologies is operating at the current time. Most of Theratechnologies' value examination focuses on studying past and present price action to predict the probability of Theratechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theratechnologies' price. Additionally, you may evaluate how the addition of Theratechnologies to your portfolios can decrease your overall portfolio volatility.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Money Managers
Screen money managers from public funds and ETFs managed around the world
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Please note, there is a significant difference between Theratechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Theratechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theratechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.